Application of drug-loaded embolic agents in the treatment of hepatocellular carcinoma

doi:10.3877/cma.j.issn.2095-5782.2020.04.014

Abstract

Abstract:

Primary liver cancer is one of the most common malignant tumors in the world with high morbidity and mortality. Transarterial chemoembolization (TACE) is the preferred treatment for advanced liver cancer. It can cause tumor ischemic necrosis while reducing systemic adverse events through the targeted delivery of embolic agent and chemotherapy drug. The embolic agent plays a crucial role in the treatment of liver cancer. At present, many embolic agents can be combined with chemotherapy drugs through various drug-loaded mechanisms, and they are further applied in the treatment of liver cancer. This article reviews the application of drug-loaded embolic agents in the treatment of liver cancer.

Key words: Primary liver cancer, Transarterial chemoembolization, Embolic agents, Drug-loaded mechanism

Qin Shi, Chen Zhou, Jiacheng Liu, Songjiang Huang, Chongtu Yang, Bin Xiong. Application of drug-loaded embolic agents in the treatment of hepatocellular carcinoma[J]. Chinese Journal of Interventional Radiology(Electronic Edition), 2020, 08(04): 364-369.

/ / Recommend

Add to citation manager EndNote|Ris|BibTeX

URL: https://zhjrfsxdzzz.cma-cmc.com.cn/EN/10.3877/cma.j.issn.2095-5782.2020.04.014

https://zhjrfsxdzzz.cma-cmc.com.cn/EN/Y2020/V08/I04/364

Figures/Tables 1

References 35

[1]	Villanueva A. Hepatocellular carcinoma[J]. N Engl J Med, 2019, 380(15): 1450-1462.
[2]	European Association for the Study of the Liver. EASL clinical practice guidelines: management of hepatocellular carcinoma[J].J Hepatol, 2018, 69(1): 182-236.
[3]	Lewis AL, Gonzalez MV, Lloyd AW, et al. DC bead: in vitro characterization of a drug-delivery device for transarterial chemoembolization[J]. J Vasc Interv Radiol, 2006, 17(2 Pt 1): 335-342.
[4]	Liapi E, Geschwind JF. Transcatheter arterial chemoembolization for liver cancer: is it time to distinguish conventional from drug-eluting chemoembolization?[J]. Cardiovasc Intervent Radiol, 2011, 34(1): 37-49.
[5]	Alshehri AM, Wilson OC, Dahal B, et al. Magnetic nanoparticle-loaded alginate beads for local micro-actuation of in vitro tissue constructs[J]. Colloids Surf B Biointerfaces, 2017, 159: 945-955.
[6]	Guiu B, Hincapie G, Thompson L, et al. An in vitro evaluation of four types of drug-eluting embolics loaded with idarubicin[J].J Vasc Interv Radiol, 2019, 30(8): 1303-1309.
[7]	Song MJ, Park CH, Kim JD, et al. Drug-eluting bead loaded with doxorubicin versus conventional lipiodol-based transarterial chemoembolization in the treatment of hepatocellular carcinoma: a case-control study of Asian patients[J]. Eur J Gastroenterol Hepatol, 2011, 23(6): 521-527.
[8]	Golfieri R, Giampalma E, Renzulli M, et al. Randomised controlled trial of doxorubicin-eluting beads vs conventional chemoembolisation for hepatocellular carcinoma[J]. Br J Cancer, 2014, 111(2): 255-264.
[9]	Sacco R, Bargellini I, Bertini M, et al. Conventional versus doxorubicin-eluting bead transarterial chemoembolization for hepatocellular carcinoma[J]. J Vasc Interv Radiol, 2011, 22(11): 1545-1552.
[10]	Zhang S, Huang C, Li Z, et al. Comparison of pharmacokinetics and drug release in tissues after transarterial chemoembolization with doxorubicin using diverse lipiodol emulsions and CalliSpheres beads in rabbit livers[J]. Drug Deliv, 2017, 24(1): 1011-1017.
[11]	Liang B, Zhao D, Liu Y, et al. Chemoembolization of liver cancer with doxorubicin-loaded CalliSpheres microspheres: plasma pharmacokinetics, intratumoral drug concentration, and tumor necrosis in a rabbit model[J]. Drug Deliv Transl Res, 2020, 10(1): 185-191.
[12]	Liang B, Xiang H, Ma C, et al. Comparison of chemoembolization with CalliSpheres microspheres and conventional chemoembolization in the treatment of hepatocellular carcinoma: a multicenter retrospective study[J]. Cancer Manag Res, 2020, 12: 941-956.
[13]	Wang CY, Xia JG, Yang ZQ, et al. Transarterial chemoembolization with medium-sized doxorubicin-eluting Callisphere is safe and effective for patients with hepatocellular carcinoma[J]. Sci Rep, 2020, 10(1): 4434.
[14]	Malagari K, Pomoni M, Moschouris H, et al. Chemoembolization of hepatocellular carcinoma with HepaSphere 30-60 μm. Safety and efficacy study[J]. Cardiovasc Intervent Radiol, 2014, 37(1): 165-175.
[15]	Guiu B, Colombat S, Piron L, et al. Transarterial chemoembolization of hepatocellular carcinoma with idarubicin-loaded tandem drug-eluting embolics[J]. Cancers (Basel), 2019, 11(7).
[16]	Aliberti C, Carandina R, Sarti D, et al. Hepatic arterial infusion of polyethylene glycol drug-eluting beads for primary and metastatic liver cancer therapy[J]. Anticancer Res, 2016, 36(7): 3515-3521.
[17]	Sharma KV, Bascal Z, Kilpatrick H, et al. Long-term biocompatibility, imaging appearance and tissue effects associated with delivery of a novel radiopaque embolization bead for image-guided therapy[J]. Biomaterials, 2016, 103: 293-304.
[18]	Levy EB, Krishnasamy VP, Lewis AL, et al. First human experience with directly image-able iodinated embolization microbeads[J]. Cardiovasc Intervent Radiol, 2016, 39(8): 1177-1186.
[19]	Chung EY, Kim HM, Lee GH, et al. Design of deformable chitosan microspheres loaded with superparamagnetic iron oxide nanoparticles for embolotherapy detectable by magnetic resonance imaging[J]. Carbohydr Polym, 2012, 90(4): 1725-1731.
[20]	Li ZY, Qin XY, Guo LY, et al. Poly(acrylic acid) microspheres loaded with superparamagnetic iron oxide nanoparticles for transcatheter arterial embolization and MRI detectability: in vitro and in vivo evaluation[J]. Int J Pharm, 2017, 527(1-2): 31-41.
[21]	Wang Q, Qian K, Liu S, et al. X-ray visible and uniform alginate microspheres loaded with in situ synthesized BaSO₄ nanoparticles for in vivo transcatheter arterial embolization[J]. Biomacromolecules, 2015, 16(4): 1240-1246.
[22]	Zeng J, Li L, Zhang H, et al. Radiopaque and uniform alginate microspheres loaded with tantalum nanoparticles for real-time imaging during transcatheter arterial embolization[J]. Theranostics, 2018, 8(17): 4591-4600.
[23]	Iezzi R, Pompili M, Rinninella E, et al. TACE with degradable starch microspheres (DSM-TACE) as second-line treatment in HCC patients dismissing or ineligible for sorafenib[J]. Eur Radiol, 2019, 29(3): 1285-1292.
[24]	Tang S, Zhou H, Wu Q, et al. Porous PLGA microspheres with recruited ions and doxorubicin for triple-combination therapy of larger hepatocellular carcinoma[J]. J Mater Chem B, 2017, 5(45): 9025-9032.
[25]	Choi JW, Park JH, Cho HR, et al. Sorafenib and 2,3,5-triiodobenzoic acid-loaded imageable microspheres for transarterial embolization ofa liver tumor[J]. Sci Rep, 2017, 7(1): 554.
[26]	Wang Y, Benzina A, Molin DGM, et al. Preparation and structure of drug-carrying biodegradable microspheres designed for transarterial chemoembolization therapy[J]. J Biomater Sci Polym Ed, 2015, 26(2): 77-91.
[27]	Wang Y, Molin DGM, Sevrin C, et al. In vitro and in vivo evaluation of drug-eluting microspheres designed for transarterial chemoembolization therapy[J]. Int J Pharm, 2016, 503(1-2): 150-162.
[28]	Zhao H, Zheng C, Feng G, et al. Temperature-sensitive poly(N-isopropylacrylamide-co-butyl methylacrylate) nanogel as an embolic agent: distribution, durability of vascular occlusion, and inflammatory reactions in the renal artery of rabbits[J]. AJNR Am J Neuroradiol, 2013, 34(1): 169-176.
[29]	Qian K, Ma Y, Wan J, et al. The studies about doxorubicin-loaded p(N-isopropyl-acrylamide-co-butyl methylacrylate) temperature-sensitive nanogel dispersions on the application in TACE therapies for rabbit VX2 liver tumor[J]. J Control Release, 2015, 212: 41-49.
[30]	Huang L, Shen M, Li R, et al. Thermo-sensitive composite hydrogels based on poloxamer 407 and alginate and their therapeutic effect in embolization in rabbit VX2 liver tumors[J]. Oncotarget, 2016, 7(45): 73280-73291.
[31]	Poursaid A, Jensen MM, Nourbakhsh I, et al. Silk-elastinlike protein polymer liquid chemoembolic for localized release of doxorubicin and sorafenib[J]. Mol Pharm, 2016, 13(8): 2736-2748.
[32]	Lym JS, Nguyen QV, Ahn DW, et al. Sulfamethazine-based pH-sensitive hydrogels with potential application for transcatheter arterial chemoembolization therapy[J]. Acta Biomater, 2016, 41: 253-263.
[33]	Nguyen QV, Lym JS, Huynh CT, et al. A novel sulfamethazine-based pH-sensitive copolymer for injectable radiopaque embolic hydrogels with potential application in hepatocellular carcinoma therapy[J]. Polym Chem, 2016, 7(37): 5805-5818.
[34]	Huynh CT, Nguyen QV, Lym JS, et al. Intraarterial gelation of injectable cationic pH/temperature-sensitive radiopaque embolic hydrogels in a rabbit hepatic tumor model and their potential application for liver cancer treatment[J]. RSC Adv, 2016, 6(53): 47687-47697.
[35]	Hu J, Albadawi H, Chong BW, et al. Advances in biomaterials and technologies for vascular embolization[J]. Adv Mater, 2019, 31(33): e1901071.

DEB产品	厂家	规格型号	载药机制	治疗药物	应用实例	疗效
DC Bead	英国Biocompatibles公司	100～300 300～500 μm 500～700 μm 700～900 μm	离子交换	阿霉素表阿霉素伊立替康	DEB-TACE对比cTACE治疗HCC患者的随机对照研究^[8]	1年OS：86.2% vs 83.5%；2年OS：56.8% vs 55.4%
CalliSphere可载药微球	中国恒瑞医药公司	100～300 μm 300～500 μm 500～700 μm 700～900 μm 900～1200 μm	离子交换	阿霉素表阿霉素伊立替康三氧化二砷奥沙利铂长春瑞滨	DEB-TACE对比cTACE治疗中国HCC患者的多中心回顾性研究^[12]	PFS：25.3个月vs 24.2个月；OS：27.8个月vs 25.3个月
HepaSphere / QuadraSphere微球	美国BioSphere医药公司	30～60 μm 50～100 μm 100～150 μm 150～200 μm	溶胀机制离子交换	阿霉素表阿霉素奥沙利铂	HepaSphere-TACE治疗HCC的安全性和有效性^[14]	CR：17.8%；ORR：68.9%；1年OS：100%
Tandem微球	美国波士顿科学公司	40 μm 40～75 μm 75 μm 100 μm	离子交换	阿霉素表阿霉素伊达比星伊立替康	Tandem-TACE治疗HCC的有效性^[15]	ORR：65%；OS：34.6个月
LifePearl微球	比利时泰尔茂欧洲分公司	100～200 μm	离子交换	阿霉素伊立替康	20例不可切除的原发性肝癌或肝转移瘤^[16]	CR：63％；ORR：> 80%；治疗期间无并发症发生

DEB产品	厂家	规格型号	载药机制	治疗药物	应用实例	疗效
DC Bead	英国Biocompatibles公司	100～300 300～500 μm 500～700 μm 700～900 μm	离子交换	阿霉素表阿霉素伊立替康	DEB-TACE对比cTACE治疗HCC患者的随机对照研究^[8]	1年OS：86.2% vs 83.5%；2年OS：56.8% vs 55.4%
CalliSphere可载药微球	中国恒瑞医药公司	100～300 μm 300～500 μm 500～700 μm 700～900 μm 900～1200 μm	离子交换	阿霉素表阿霉素伊立替康三氧化二砷奥沙利铂长春瑞滨	DEB-TACE对比cTACE治疗中国HCC患者的多中心回顾性研究^[12]	PFS：25.3个月vs 24.2个月；OS：27.8个月vs 25.3个月
HepaSphere / QuadraSphere微球	美国BioSphere医药公司	30～60 μm 50～100 μm 100～150 μm 150～200 μm	溶胀机制离子交换	阿霉素表阿霉素奥沙利铂	HepaSphere-TACE治疗HCC的安全性和有效性^[14]	CR：17.8%；ORR：68.9%；1年OS：100%
Tandem微球	美国波士顿科学公司	40 μm 40～75 μm 75 μm 100 μm	离子交换	阿霉素表阿霉素伊达比星伊立替康	Tandem-TACE治疗HCC的有效性^[15]	ORR：65%；OS：34.6个月
LifePearl微球	比利时泰尔茂欧洲分公司	100～200 μm	离子交换	阿霉素伊立替康	20例不可切除的原发性肝癌或肝转移瘤^[16]	CR：63％；ORR：> 80%；治疗期间无并发症发生

Please choose a citation manager

Content to export